Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD.

Kostikas K, Brindicci C, Patalano F.

Curr Drug Targets. 2018;19(16):1882-1896. doi: 10.2174/1389450119666180212120012.

2.

Effects of beclomethason/formoterol and budesonide/formoterol fixed combinations on lung function and airway inflammation in patients with mild to moderate asthma--an exploratory study.

Kirsten AM, Watz H, Brindicci C, Piccinno A, Magnussen H.

Pulm Pharmacol Ther. 2015 Apr;31:79-84. doi: 10.1016/j.pupt.2014.08.007. Epub 2014 Sep 4.

PMID:
25194884
3.

Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination.

Barnes N, van Noord JA, Brindicci C, Lindemann L, Varoli G, Perpiña M, Guastalla D, Casula D, Patel S, Chanez P; FACTO (Foster® As Complete Treatment Option) Study Group.

Pulm Pharmacol Ther. 2013 Oct;26(5):555-61. doi: 10.1016/j.pupt.2013.01.011. Epub 2013 Mar 22.

PMID:
23524015
4.

Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial.

O'Connor BJ, Collarini S, Poli G, Brindicci C, Spinola M, Acerbi D, Barnes PJ, Leaker B.

BMC Pulm Med. 2011 Dec 21;11:60. doi: 10.1186/1471-2466-11-60.

5.

Nitric oxide synthase isoenzyme expression and activity in peripheral lung tissue of patients with chronic obstructive pulmonary disease.

Brindicci C, Kharitonov SA, Ito M, Elliott MW, Hogg JC, Barnes PJ, Ito K.

Am J Respir Crit Care Med. 2010 Jan 1;181(1):21-30. doi: 10.1164/rccm.200904-0493OC. Epub 2009 Sep 24.

6.

Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine.

Osoata GO, Hanazawa T, Brindicci C, Ito M, Barnes PJ, Kharitonov S, Ito K.

Chest. 2009 Jun;135(6):1513-1520. doi: 10.1378/chest.08-2105. Epub 2009 Feb 2.

PMID:
19188555
7.

Effects of aminoguanidine, an inhibitor of inducible nitric oxide synthase, on nitric oxide production and its metabolites in healthy control subjects, healthy smokers, and COPD patients.

Brindicci C, Ito K, Torre O, Barnes PJ, Kharitonov SA.

Chest. 2009 Feb;135(2):353-367. doi: 10.1378/chest.08-0964. Epub 2008 Aug 21.

PMID:
18719059
8.

Effect of an inducible nitric oxide synthase inhibitor on differential flow-exhaled nitric oxide in asthmatic patients and healthy volunteers.

Brindicci C, Ito K, Barnes PJ, Kharitonov SA.

Chest. 2007 Aug;132(2):581-8. Epub 2007 Jun 5.

PMID:
17550932
9.

Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity.

Brindicci C, Ito K, Barnes PJ, Kharitonov SA.

Chest. 2007 May;131(5):1353-62.

PMID:
17494785
10.

Measurement of bronchial and alveolar nitric oxide production in normal children and children with asthma.

Paraskakis E, Brindicci C, Fleming L, Krol R, Kharitonov SA, Wilson NM, Barnes PJ, Bush A.

Am J Respir Crit Care Med. 2006 Aug 1;174(3):260-7. Epub 2006 Apr 20.

PMID:
16627868
11.

Effects of aerosolized adenosine 5'-triphosphate vs adenosine 5'-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma.

Basoglu OK, Pelleg A, Essilfie-Quaye S, Brindicci C, Barnes PJ, Kharitonov SA.

Chest. 2005 Oct;128(4):1905-9.

PMID:
16236834
12.

Exhaled nitric oxide from lung periphery is increased in COPD.

Brindicci C, Ito K, Resta O, Pride NB, Barnes PJ, Kharitonov SA.

Eur Respir J. 2005 Jul;26(1):52-9.

13.

Hypercapnia in overlap syndrome: possible determinant factors.

Resta O, Foschino Barbaro MP, Brindicci C, Nocerino MC, Caratozzolo G, Carbonara M.

Sleep Breath. 2002 Mar;6(1):11-8.

PMID:
11917259

Supplemental Content

Loading ...
Support Center